Alphyn Biologics is an Annapolis, Md.- and Cincinnati, Ohio-based clinical-stage dermatology business that has developed first-in-class multitarget therapies and closed the Series A financing round of approximately $3.3m.
The round was directed by Queen City Angels, with participation from the Angel Physicians Fund and Serial Stage Venture Partners.
The company has raised $6.7 million, which includes an initial round of more than $1 million and a subsequent round greater than 2 million dollars. It plans to use the funds to conduct a Phase2a clinical trial of AB101a, which is its principal drug candidate to treat moderate-to-moderate atopic dermatology (AD), the most prevalent type of eczema.
CEO Neal Koller leads the company; Alphyn Biologics is a dermatology firm in the clinical stage that is developing the first multi-target therapy in the world for the most severe and common skin disorders built on its AB-101 platform. The lead product candidate, AB101a, is a topical therapy for Atopic Dermatitis (AD), the most frequent type of eczema.
The drug is in Phase 2 clinical trial. AB-101a, a non-steroidal, targets common bacteria such as Staph and highly drug-resistant methicillin-resistant Staph (MRSA) that worsen AD and prevent its healing.
The company also has an owned and controlled affiliate in Australia.
